<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_NUDT_CHINA_Design skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:NUDT CHINA/Design</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="container"><DIV class="row clearfix"><NAV class="navbar navbar-default navbar-fixed-top" role="navigation" style="top:14px;font-size: 100%;background-color: rgba(0, 0, 0, 0.48);border-color: rgba(0,0,0,.075);"><DIV class="collapse navbar-collapse navbar-inverse" id="bs-example-navbar-collapse-1" style="background-color: rgba(0, 0, 0, 0.23);"><UL class="nav navbar-nav"><LI class=""><A href="https://2018.igem.org/Team:NUDT_CHINA">HOME</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">TEAM</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Team">Team Members</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Collaborations"> Collaborations </A></LI></UL><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">PROJECT</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Description">Description</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Design">Design</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Experiments">Experiments</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Notebook">Notebook</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/InterLab">InterLab</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Results">Results</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Demonstrate">Demonstrate</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Improve">Improve</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Attributions">Attributions</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">MODEL</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Model">Model</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Model/Overview">Overview</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Model/Basic Design">Basic Design</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Model/Deduction">Deduction</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Model/Discussion">Discussion</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">PARTS</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Parts">Parts Overview</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Basic_Part">Basic Parts</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Composite_Part">Composite Parts</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Part_Collection">Part Collection</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Safety">SAFETY</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Human Practices</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Human_Practices">Human Practices</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Public_Engagement">Education &amp; Engagement</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">AWARDS</A></LI><LI><A href="https://2018.igem.org/Team:NUDT_CHINA/Model">Model</A></LI></DIV></NAV></DIV></DIV><DIV class="col-md-12 column" style="width:100%;height:250px;background-size:contain;0px -100px; background-image:url(https://static.igem.org/mediawiki/2018/6/66/T--NUDT_CHINA--banner_project_design.jpg);background-repeat:no-repeat;"><P style="font-size:36px;margin: 0 0%;padding: 5% 0 0 10%;color: white;">Designed Protein Degradation Method Based on</P><P style="font-size:36px;margin: 0 0%;padding: 0 0 0 10%;color: white;">Trim21 And Nanobody                 -- Design</P></DIV><DIV class="container"><DIV class="row clearfix"><DIV class="container" style="margin-top: 280px"><DIV class="row" style="margin-top: 25px"><DIV class="col-md-push-1 col-md-10" alt="this is a title model"><H1 style="font-size: 40px">PR PREDATOR-An improved protein degradation method based on ectopic expression of TRIM21 and recombinant antibody</H1></DIV><DIV class="col-md-push-1 col-md-10" alt="this is a paragraph model"><P>Design:
1. The design of ectopic expression of recombinant antibody.
To overcome the difficulty of expressing the multi-chain natural antibody in cells, we choose to express the single-domain antibody in our design. Single-domain antibodies, exampled by nanobody which identified as heavy-chain antibodies found in camelids, and scFv, a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of immunoglobulins, were able to bind selectively to a specific antigen with reduced amino acid number. However, the single-domain antibody lacks the constant Fc region, which is vital for the recognition of Tim21. To utilize the convenience of expressing single-domain antibody and bridge the recognition of Tim21 to single-domain antibody, in our design, the single-domain antibody was fused with human IgG-Fc domain. 
By scanning reported single-domain antibodies in  literatures, we built a data sheet with all available single-domain antibodies and their target proteins enclosed. This data sheet can provide a sound basis for standardization of these nanobodies for further usage. The plasmid expressing the PR PREDATOR system was constructed by putting the coding regions of HA-Trim21 and nanobody-IgG Fc under CMV promoter. The HA-Trim21 and nanobody-IgG Fc regions were separated by P2A sequence to achieve bicistronic expression (Figure 1).  
Theoretically, when the recombinant plasmids were introduced into cells, the single-domain antibody will bind to target proteins with high affinity, forming tight complexes, and then Trim21 would bind to the Fc domain of antibodies with high affinity and recruits the ubiquitin-proteasome system to antibody-bound complex, finally leading to their destruction. 

                                        </P></DIV><DIV class="col-md-12 column" alt="this is a picture model"><DIV class="col-md-8 col-md-push-2 thumbnail" alt="content_pictute"><P class="photo_detail">Figure 1. Schematic representation of the degradation process of our scheme</P></DIV><DIV class="col-md-push-1 col-md-10" alt="this is a paragraph model"><P>2. Proof of concept
As a Proof of concept of our idea, we constructed GFP nanobody sequence into our PR PREDATOR system to make the GFP PREDATOR. A high-yield exogenous expression of GFP could provide us a visible approach to evaluate if our PREDATOR would work. For such matter, GFP expression plasmid and GFP PREDATOR plasmid were co-transfected in HEK293T or Hela cells, GFP fluorescence was observed under fluorescence microscope and GFP protein expression was detected by western blotting (Figure2A).
</P><P class="photo_detail">Figure 2. Proof of concept and demonstration design of our project</P><DIV><DIV class="col-md-push-1 col-md-10" alt="this is a paragraph model"><P>3. Further demonstration
For a more complicated demonstration, the endogenous receptor tyrosine-protein kinase erbB-3 was selected as our target protein which has been reported to play important roles in the poliferation, metastasis, and drug resistance in multiple cancers. Due to its significance, many antibodies of erbB3 have been used in clinical trials for the treatment of multiple kinds of cancer (such as MM-121, AMG 888 (U3-1287), TK-A3, TK-A4, AV-203, LJM716, MEHD7945A, MEHD7945A, MM-111 and MM-141). In our demonstration, the erbB-3 scFv antibody sequence would be expressed along with trim21 in MCF7 cells and directly functions on erbB-3 to bring down its level and inhibit MCF7 cells proliferation. The erbB3 protein expression could be detected by western blotting and influence on the proliferation of MCF7 cells could be verified by CCK-8 assay or colony formation assay (Figure2B).
</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>